Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109210 | 1.00 | CHRNA7 (0.33) | CHRNA7MAPTDRD2SIGMAR1PHGDH | |
| SCHEMBL20109216 | 0.89 | MAPT (0.37) | CHRNA7MAPTDRD2SIGMAR1PHGDH | |
| SCHEMBL20109208 | 0.84 | SMN1; SMN2 (0.40) | CHRNA7MAPTTSHRMEN1KMT2A | |
| SCHEMBL20109224 | 0.82 | CHRNA7 (0.32) | CHRNA7MAPTDRD2SIGMAR1 | |
| SCHEMBL20109212 | 0.82 | TRPA1 (0.32) | CHRNA7MAPTDRD2SIGMAR1 | |
| SCHEMBL20109137 | 0.82 | CHRNA7 (0.33) | CHRNA7MAPTDRD2SIGMAR1TSHR | |
| SCHEMBL20109236 | 0.82 | CHRNA7 (0.33) | CHRNA7MAPTDRD2SIGMAR1TSHR | |
| SCHEMBL20109141 | 0.82 | CHRNA7 (0.33) | CHRNA7MAPTDRD2SIGMAR1TSHR | |
| SCHEMBL20109233 | 0.82 | CHRNA7 (0.33) | CHRNA7MAPTDRD2SIGMAR1TSHR | |
| SCHEMBL20113894 | 0.81 | RAB9A (0.37) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | CHRNA7 3780/4885MAPT 4371/4885DRD2 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.